Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6056-6067

  Manning, Jessica ^a   Vanachayangkul, Pattaraporn ^a   Lon, Chanthap ^a   Spring, Michele ^a   So, Mary ^c   Sea, Darapiseth ^b   Se, Youry ^a   Somethy, Sok ^c   Phann, Sut Thang ^b   Chann, Soklyda ^a   Sriwichai, Sabaithip ^a   Buathong, Nillawan ^a   Kuntawunginn, Worachet ^a   Mitprasat, Mashamon ^a   Siripokasupkul, Raveewan ^a   Teja Isavadharm, Paktiya ^a   Soh, Eugene ^d   Timmermans, Ans ^a   Lanteri, Charlotte ^a   Kaewkungwal, Jaranit ^e   Auayporn, Montida ^e   Tang, Douglas ^f   Chour, Char Meng ^b   Prom, Satharath ^c   Haigney, Mark ^d   Cantilena, Louis ^d   Saunders, David ^a   more..

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^c Royal Cambodian Armed Forces   (Cambodia)

^d Uniformed Services University of the Health Sciences   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Fast Track Drugs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; PIPERAQUINE; PLACEBO; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARMY; ARTICLE; CAMBODIA; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART REPOLARIZATION; HUMAN; HYPERTROPHY; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM VIVAX MALARIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIMULATION; SINUS ARRHYTHMIA; SINUS BRADYCARDIA; SINUS TACHYCARDIA; YOUNG ADULT; CHEMICALLY INDUCED; HEART ARRHYTHMIA;

ADULT; ANTIMALARIALS; ARRHYTHMIAS, CARDIAC; ARTEMISININS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALARIA; MALE; QUINOLINES; YOUNG ADULT;

EID: 84907914805     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02667-14     Document Type: Article

References (36)

1. World Health Organization. 2013. World malaria report 2013. World Health Organization, Geneva, Switzerland.
2. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM. 2011. Artesunate dose escalation for the treatment of un-complicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One 6:e19283. http://dx.doi.org/10.1371 /journal.pone.0019283.
3. Zwang J, Ashley EA, Karema C, DAlessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F. 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4:e6358. http://dx.doi.org/10.1371 /journal.pone.0006358.
4. Naing C, Mak JW, Aung K, Wong JY. 2013. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Trans. R. Soc. Trop. Med. Hyg. 107:65-73. http://dx.doi.org/10.1093/trstmh/trs019.
5. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P. 2013. Efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57: 818-826. http://dx.doi.org/10.1128/AAC.00686-12.
6. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, Cheah P, Singhasivanon P, White NJ, Lindegårdh N, Nosten F. 2012. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob. Agents Chemother. 56:1571-1577. http: //dx.doi.org/10.1128/AAC.05877-11.
7. Keating GM. 2012. Eurartesim: a guide to its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs Ther. Perspect. 28: (10) 1-5. http://dx.doi.org/10.1007/BF03262125.
8. Sigma-Tau Industrie Farmaceutiche Riunite s.p.a. Eurartesim. Annex I. Summary of product characteristics. Sigma-Tau Industrie Farmaceutiche Riunite s.p.a., Rome, Italy, http://www.ema.europa.eu /docs/en-GB/document-library/EPAR-Product-Information/human /001199/WC500118313.pdf.
9. Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokunthea S, Sophorn L, Zhou C, Deng C, Wang Q, Li G. 2011. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar. J. 10:231. http://dx.doi. org/10.1186/1475-2875-10-231.
10. Hung T-Y, Davis TME, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
11. WHO Working Group. 1989. Glucose-6-phosphate dehydrogenase deficiency. Bull. World Health Organ. 67:601-611.
12. Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, Gosi P, Lanteri C, Chaorattanakawee S, Sriwichai S, Chann S, Kuntawunginn W, Buathong N, Nou S, Walsh DS, Tyner SD, Juliano JJ, Lin J, Spring M, Bethell D, Kaewkungwal J, Tang D, Chuor CM, Satharath P, Saunders D. 2014. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in Northern Cambodia: an open-label randomized trial. PLoS One 9:e93138. http://dx.doi.org/10.1371/journal.pone.0093138.
13. National Cancer Institute. 2010. Common terminology criteria for adverse events (CCTCAE), version 4.03. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD.
14. Moss AJ. 1993. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am. J. Cardiol. 72:23B-25B. http://dx.doi.org/10.1016/0002-9149(93)90036-0.
15. Kannankeril P, Roden DM, Darbar D. 2010. Drug-induced long QT syndrome. Pharmacol. Rev. 62:760-781. http://dx.doi.org/10.1124/pr .110.003723.
16. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F. 2007. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 77:447-450.
17. Karunajeewa H, Lim C, Hung T-Y, Ilett KF, Denis MB, Socheat D, Davis TME. 2004. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br. J. Clin. Pharmacol. 57:93-99. http://dx.doi.org/10.1046/j .1365-2125.2003.01962.x.
18. European Medicines Agency. 2011. Eurartesim assessment report. EMA/ 739355/2011. Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom, http://www.ema. europa.eu/docs/en-GB/doeument-library/EPAR-Public-assessment -report/human/001199/WC500118116.pdf.
19. White NJ. 2007. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7:549-558. http://dx.doi.org/10.1016/51473-3099(07)70187-1.
20. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukrittayakamee S, Pukittayakamee S. 2010. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 5:e11880. http://dx.doi.org/10.1371/journal.pone.0011880.
21. Bas sat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, DAlessandro U. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 4:e7871. http://dx.doi.org/10.1371/journal.pone.0007871.
22. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. 2004. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur. J. Pharmacol. 484:41-48. http: //dx.doi.org/10.1016/j.ejphar.2003.11.003.
23. Riou B, Barriot P, Rimailho A, Baud FJ. 1988. Treatment of severe chloroquine poisoning. N. Engl. J. Med. 318:1-6. http://dx.doi.org/10 .1056/NEJM198801073180101.
24. Tsuboi M, Antzelevitch C. 2006. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm. 3:328-335. http://dx.doi.org/10.1016/j.hrthm.2005.11 .026.
25. Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan G-X, Funck-Brentano C. 2012. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimi-crob. Agents Chemother. 56:3261-3270. http://dx.doi.org/10.1128/AAC .05688-11.
26. Postema PG, Ritsema van Eck HJ, Opthof T, van Herpen G, van Dessel PFHM, Priori SG, Wolpert C, Borggrefe M, Kors JA, Wilde AAM. 2009. IK1 modulates the U-wave: insights in a 100-year-old enigma. Heart Rhythm. 6:393-400. http://dx.doi.org/10.1016/j.hrthm.2008.11.024.
27. Zhang H, Garratt C, Zhu J, Holden A. 2005. Role of up-regulation of in action potential shortening associated with atrial fibrillation in humans. Cardiovascular Res. 66:493-502. http://dx.doi.org/10.1016/j.cardiores .2005.01.020.
28. Hai TN, Hietala SF, Van Huong N, Ashton M. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107:145-149. http://dx.doi.org/10.1016/j.actatropica .2008.05.013.
29. Annerberg A, Lwin KM, Lindegardh N, Khrutsawadchai S, Ashley E, Day NPJ, Singhasivanon P, Tarning J, White NJ, Nosten F. 2011. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55:3971-3976. http://dx.doi.org/10.1128/AAC.00279-11.
30. Sim I-K, Davis TME, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49:2407-2411. http://dx.doi.org/10.1128/AAC.49.0.2407-2411 .2005.
31. Nguyen TC, Nguyen NQ, Nguyen XT, Bui D, Travers T, Edstein MD. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620-623.
32. Na-Bangchang K, Krudsood S, Silachamroon U, Molunto P, Tasanor O, Chalermrut K, Tangpukdee N, Matangkasombut O, Kano S, Looareesuwan S. 2004. The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J. Trop. Med. Public Health 35:575-582.
33. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck H-P, Marrast A-C, Cousin M, Rosenthal PJ. 2011. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am. J. Trop. Med. Hyg. 85:793-804. http://dx.doi.org/30.4269/ajtmh.2011.11 -0069.
34. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F. 1999. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60:547-555.
35. Kshirsagar NA, Gogtay NJ, Moorthy NS, Garg MR, Dalvi SS, Chogle AR, Sorabjee JS, Marathe SN, TiIve GH, Bhatt AD, Sane SP, Mull R, Gathmann L 2000. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am. J. Trop. Med. Hyg. 62:402-408.
36. Liu C, Zhang R, Hong X, Huang T, Mi S, Wang N. 2007. Pharmaco-kinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zacchi 127:1709-1714.